H.C. Wainwright adjusted the firm’s price target on BioCardia to $25 from $4 and keeps a Buy rating on the shares following the recent 1-for-15 reverse stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCDA:
- BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
- BioCardia submits for FDA approval of Morph DNA Steerable Introducer family
- BioCardia Initiates Phase III Trial for Heart Failure Treatment
- BioCardia announces confirmatory Phase 3 trial of CardiAMP commenced enrollment
- Biotech Alert: Searches spiking for these stocks today